The correlation between hemoglobin A 1c (Hb A 1c ) and risk for complications in diabetic patients heightens the need to measure Hb A 1c with accuracy. We evaluated the current performance for measuring Hb A 1c in the Asian and Pacific region by examining data submitted by laboratories participating in the Taiwan proficiency-testing program.
performance of Hb A 1c testing in the Asian and Pacific laboratories during the 4 years of assessment.
Hemoglobin A 1c (Hb A 1c ) 6 measurements obtained for a period of 2-3 months provide an important index for assessing glycemic control in patients with diabetes. Results from the Diabetes Control and Complications Trial (DCCT) in patients with type 1 diabetes (1 ) and the United Kingdom Prospective Diabetes Study in patients with type 2 diabetes (2, 3 ) indicate that Hb A 1c is directly related to the risk of development and progression of diabetic complications. The National Glycohemoglobin Standardization Program (NGSP) was established in 1996 to standardize Hb A 1c testing, so that clinical laboratory results would be traceable to the clinical studies and outcomes from DCCT and the United Kingdom Prospective Diabetes Study (4, 5 ) . Guidelines for the management of diabetes rely closely on the measurement of Hb A 1c (6 -8 ) .
Maintenance of Hb A 1c at Ͻ7.0% has been recommended for the effective treatment of diabetes (9 ) . In addition, recent studies have suggested that Hb A 1c can be used for the screening and diagnosis of diabetes (10 -12 ) . Thus, precise and accurate measurement of Hb A 1c is critical and essential for proper diabetes care.
Proficiency testing (PT) that is accuracy based is important for improving and maintaining the quality of laboratory test results. Both imprecision and bias influence PT performance. Studies have suggested that maintaining a CV of less than one-third of the PT limit will guarantee passing PT events, given a bias less than one-fifth of the PT limit (13, 14 ) .
The Taiwan The target values for the survey samples were assigned by 2 NGSP secondary reference laboratories (SRLs). The SRLs analyzed each sample in triplicate on 2 separate days; the mean of all results was used as the assigned target value. The SRLs used Tosoh ionexchange chromatography and Primus affinity chromatography, and each method was calibrated and traceable to the DCCT reference method.
Participants' results were evaluated according to several different accuracy-based grading schemes, the criteria of TSLM (Ϯ7% of the NGSP target), the College of American Pathologists (CAP; 2008 criterion Ϯ12% of the NGSP-target), and the Royal College of Pathologists of Australasia's Quality Assurance Program (Ϯ0.5% Hb A 1c if Ͻ10.0% Hb A 1c , or Ϯ5% of the DCCT-target if Ն10.0% Hb A 1c ). Acceptable performance was deemed as at least 80% of PT samples within the acceptable limits. We also analyzed the results obtained from 4 consecutive years, including method-specific median, mean, interlaboratory imprecision (CV), and bias for methods with participant numbers Ն10. The observed trueness (bias) for each method was assessed from the difference between the method-specific mean and the NGSP target value. Measurement uncertainty (MU) for each method was calculated from the square root of the sum of the squares of method-specific bias and method-specific SD, with a coverage factor of 2 (15 ). The weighting a MU (expanded uncertainty), calculated from the square root of the sum of the squares of method-specific bias and method-specific SD, with a coverage factor of 2.
factor for the weighted mean was the number of laboratories in each method-specific group. Laboratories participating in the Hb A 1c Survey in Taiwan and the Asian Pacific region included hospitalbased laboratories, freestanding facilities, and physician office laboratories. Each year there were 208 -276 laboratories in Taiwan and 13-15 laboratories outside Taiwan enrolled in this program. The participants located outside Taiwan included Australia (n ϭ 1), Hong Kong (n ϭ 1), Indonesia (n ϭ 2), India (n ϭ 2), Korea (n ϭ 1), Malaysia (n ϭ 3), Pakistan (n ϭ 2), Singapore (n ϭ 4), Thailand (n ϭ 1), and Vietnam (n ϭ 1 In 2008, the CVs of HPLC-based methods were 1.1%-4.1% at Hb A 1c concentrations of 4.8%-9.1%, whereas the interlaboratory CVs for immunoassays were 3.8%-6.1%. There were 4 methods (Primus and Tosoh G7 Standard, G7 Variant, and A1c 2.2 Plus) having interlaboratory CVs less than one-third of the PT limit (2.3%) at Hb A 1c concentrations Ն5.0%. This interlaboratory CV is consistent with the CAP survey results, which showed CVs of 1.5%-3.5% for HPLC methods and 3.5%-8.0% for immunoassays (16 ) .
Several expert groups in laboratory medicine recommended within-laboratory and between-laboratory imprecision goals of 3% and 5%, respectively (6, 17 ) . Overall assessment revealed that the imprecision for all HPLC methods was good and fulfilled the quality goal. An optimal within-laboratory imprecision goal of 2% was advocated recently (18 ) . The comparable betweenlaboratory CV is estimated as 3.3%. However, only about one-half of analytical methods used in this survey achieved this quality goal of imprecision at all concentrations tested in 2008, and all of the methods that achieved this goal were HPLC based.
Differences between NGSP-assigned target values and method-specific median values at the low, medium, and high Hb A 1c concentrations from 7 NGSPcertified methods were within 0.4%, 0.2%, and 0.5% Hb A 1c of NGSP targets, respectively, in 2006; within 0.2%, 0.3%, and 0.6% Hb A 1c in 2007, and within 0.2%, (16 ) . The cause of the bias is unclear. However, the difference plots indicate that the bias has resolved over time. (19 ) . Our data on mean MU (0.49% Hb A 1c ) conform to the 0.5% Hb A 1c change criterion. This change criterion of a 0.5% Hb A 1c reporting unit corresponds to results within Ϯ7% of the target value in the PT scheme being adequate to meet clinical needs.
Acceptable performance for each method during the 4-year study period is shown in Fig. 1 Fig. 3) .
Studies have shown that decreases in Hb A 1c reduced the risk of complications in diabetes (3, 7 ) . Stringent analytical quality goals for Hb A 1c would provide improved precision and accuracy, facilitating better assessment of patient glycemic control. Use of pooled fresh human blood as PT survey samples was recommended to accurately assess the performance of Hb A 1c testing by avoiding potential sample matrix effects during shipping and processing. The NGSP SRL network is anchored by the DCCT reference method, which has proven to be consistent during a 25-year period (20 ) . The network is also monitored against the IFCC definitive reference method, and the uncertainty (2 SD) of values assigned by the NGSP network has been shown to be 0.10% Hb A 1c (21 ) . Thus, the contribution of the uncertainty of the NGSP value assignments to the total uncertainty of the Taiwan Proficiency Survey results is negligible. With the NGSP-assigned target values, the accuracy-based Hb A 1c survey enables laboratories to evaluate harmonization among methods and traceability to the DCCT reference method (6 ) .
The improvement of interlaboratory CVs and bias and pass rate during the 4 years suggests that the PT program played a role in this improvement. The majority of the participants using NGSP-certified methods showed an acceptable Hb A 1c testing performance. Nevertheless, the deficiencies found in some laboratories confirm the need for continuing quality improvement for Hb A 1c measurement.
